Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.54 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977514 | 1.00 | PPARA (0.54) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL977513 | 1.00 | PPARA (0.54) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL5379694 | 0.89 | ESR1 (0.45) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL5379702 | 0.89 | ESR1 (0.45) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL14501971 | 0.89 | PPARA (0.50) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL3535227 | 0.89 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL3535230 | 0.89 | ESR1 (0.58) | PPARAESR1ESR2PPARGPPARD | |
| SCHEMBL2554435 | 0.88 | PPARA (0.52) | PPARAPPARGPPARD | |
| SCHEMBL5360147 | 0.87 | ESR1 (0.51) | PPARAESR1ESR2CA12CA1 | |
| SCHEMBL3965096 | 0.87 | PPARA (0.50) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3024816-B1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEV CO LLC (US) | 2020-06-03 | — | — | EP | disclosed |
| US-9562012-B2 | PPAR-sparing compounds for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562012-B2 | PPAR-sparing compounds for the treatment of metabolic diseases | METABOLIC SOLUTIONS DEVELOPMENT COMPANY, LLC (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | ALZHEIMER'S DRUG DISCOVERY FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | ALZHEIMER'S DRUG DISCOVERY FOUNDATION | 2016-06-02 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2016-02-25 | — | — | US | disclosed |
| EP-2931274-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Metabolic Solutions Development Company LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015013187-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT CO., LLC (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093114-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2012177956-A1 | PPAR-SPARING COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMAPNY, LLC (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177956-A1 | PPAR-SPARING COMPOUNDS FOR USE IN THE TREATMENT OF DIABETES AND OTHER METABOLIC DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMAPNY, LLC (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-6972294-B1 | Compounds, their preparation and use | NOVO NORDISK, A/S (DK) | 2005-12-06 | — | — | US | disclosed |
| EP-1171414-A1 | COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000063153-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051529-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND OTHER METABOLIC DISEASES | PPARD, PPARG, PPARA | PPARA 3/4885ESR1 543/4885ESR2 187/4885 |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PPARA, PPARG, PPARD | PPARA 1/4885ESR1 1636/4885ESR2 799/4885 |
| US-20160152570-A1 | PPAR-SPARING COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES | PPARG, PPARA, PPARD | PPARA 2/4885ESR1 1274/4885ESR2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.